VLPCOV-U-01

VLPCOV-U-01 is a self-amplifying mRNA (saRNA) vaccine candidate developed by VLP Therapeutics Japan for the prevention of COVID-19. Utilizing a replicon RNA platform, the vaccine is designed to replicate itself within host cells after administration, which typically results in higher and more sustained levels of antigen expression compared to conventional mRNA vaccines, potentially allowing for lower dosage requirements. VLPCOV-U-01 is specifically engineered to elicit robust T-cell immunogenicity and is being evaluated in clinical trials focusing on healthy adults with specific HLA alleles to assess its safety and ability to induce broad cellular immune responses against SARS-CoV-2.

Other names

T-cell inducing COVID-19 vaccinesaRNA Covid19 (universal)universal COVID-19 vaccine